Impact of type of dialyzable beta-blockers on subsequent risk of mortality in patients receiving dialysis: A systematic review and meta-analysis

CNU IR > Pharmacy and Science > Dept. of Health and Nutrition (including master's program) > Periodical Articles > Item 310902800/34687

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34687

题名:	Impact of type of dialyzable beta-blockers on subsequent risk of mortality in patients receiving dialysis: A systematic review and meta-analysis
作者:	Yeh, Tzu-Hsuan Tu, Kuan-Chieh Hung, Kuo-Chuan Chuang, Min-Hsiang Chen, Jui-Yi
贡献者:	Chi Mei Hospital Department of Health and Nutrition, Chia Nan University of Pharmacy & Science
关键词:	pharmacokinetics atenolol carvedilol hemodialysis hypertension metoprolol blockade failure events
日期:	2022
上传时间:	2023-12-11 14:05:11 (UTC+8)
出版者:	PUBLIC LIBRARY SCIENCE
摘要:	Background Beta-blockers has been reported to improve all-cause mortality and cardiovascular mortality in patients receiving dialysis, but type of beta-blockers (i.e., high vs. low dialyzable) on patient outcomes remains unknown. This study aimed at assessing the outcomes of patients receiving dialyzable beta-blockers (DBBs) compared to those receiving non-dialyzable beta-blockers (NDBBs). Methods We searched the databases including PubMed, Embase, Cochrane, and ClinicalTrials. gov until 28 February 2022 to identify articles investigating the impact of DBBs/NDBBs among patients with renal failure receiving hemodialysis/peritoneal dialysis (HD/PD). The primary outcome was risks of all-cause mortality, while the secondary outcomes included risk of overall major adverse cardiac event (MACE), acute myocardial infarction (AMI) and heart failure (HF). We rated the certainty of evidence (COE) by Cochrane methods and the GRADE approach. Results Analysis of four observational studies including 75,193 individuals undergoing dialysis in hospital and community settings after a follow-up from 180 days to six years showed an overall all-cause mortality rate of 11.56% (DBBs and NDBBs: 12.32% and 10.7%, respectively) without significant differences in risks of mortality between the two groups [random effect, aHR 0.91 (95% CI, 0.81-1.02), p = 0.11], overall MACE [OR 1.03 (95% CI, 0.781.38), p = 0.82], and AMI [OR 1.02 (95% CI, 0.94-1.1), p = 0.66]. Nevertheless, the pooled odds ratio of HF among patients receiving DBBs was lower than those receiving NDBB [random effect, OR 0.87 (95% CI, 0.82-0.93), p<0.001]. The COE was considered low for overall MACE, AMI and HF, while it was deemed moderate for all-cause mortality. Conclusions The use of dialyzable and non-dialyzable beta-blockers had no impact on the risk of allcause mortality, overall MACE, and AMI among dialysis patients. However, DBBs were associated with significant reduction in risk of HF compared with NDBBs. The limited number of available studies warranted further large-scale clinical investigations to support our findings.
關聯:	PLOS ONE, v.17, n.12, e0279680
显示于类别:	[Dept. of Health and Nutrition (including master's program)] Periodical Articles

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	797	检视/开启
journal.pone.0279680.pdf		1038Kb	Adobe PDF	248	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....